Alice obtained her PhD in Chemistry in the lab of Professor Raquel Lieberman at the Georgia Institute of Technology. She then joined the lab of Dr. Loren Walensky, where she is develoing novel reagents that selectively target oligomeric BAK (BAKo) to both elucidate its long-elusive structure and advance new mechanistic understanding of BAKo-mediated mitochondrial membrane permeabilization, which drives apoptotic cell death. The findings have the potential to inform new pharmacologic opportunities to trigger BAKo-mediated mitochondrial membrane permeabilization and thereby reactivate apoptosis in treatment-resistant cancer. The CCBM T32 Training Program will enable her to develop crucial scientific skills and knowledge and achieve her career goals as a future independent investigator.
Brian obtained his PhD in Chemical Biology in the lab of Professor Benjamin Davis at the University of Oxford. He then joined the lab of Dr. Cigall Kadoch, where he studies the interaction between the SWI/SNF chromatin remodeling complex and histones, the major protein component of chromatin. Brian seeks to understand how different histone variants, PTMs, and cancer associated mutations attenuate the function of the three SWI/SNF variants, cBAF, PBAF and ncBAF. Preliminary work identified that PBAF exhibits enhanced chromatin remodeling activity on nucleosomes containing the histone variant H2A.Z, in contrast to significantly lowered activity for the other SWI/SNF variants, cBAF and ncBAF. PBAF and H2A.Z also show strong codependency across many cancer types, suggesting a disease mechanism with potential therapeutic relevance. Brian aims to decipher the mechanism of this apparent PBAF specific H2A.Z interaction, validate its occurrence and role in mediating gene expression in cells, and define the consequences when either PBAF or H2A.Z contain cancer associated mutations. The CCBM T32 training program will provide Brian with the opportunity to both build on his chemical biology skillset and apply it to relevant biological problems in cancer research.
Zachary earned his PhD from Vanderbilt University in 2020. He then joined the laboratory of Dr. Myles Brown, where he studies targeted protein degradation of the transcription factor, estrogen receptor alpha (ER) in ER+ breast cancer. His research seeks to better understand the mechanism of action for selective estrogen receptor degraders (SERDs), a new class of ER antagonists that target ER protein for degradation via the ubiquitin-proteasome pathway. Utilizing a functional, genome-wide, CRISPR/Cas9 screening approach, Zachary has identified ubiquitin-proteasome genes that are required for sensitivity to SERDs. He is interested in determining if loss of these ubiquitin-proteasome pathway genes is a mechanism for ER+ breast cancer to develop SERD resistance. Furthermore, Zachary will use his screening approach to identify new therapeutic targets in SERD-resistant ER+ breast cancer. Zachary joined the CCBM T32 training program to prepare for a career as an independent researcher in the fields of oncology and pharmacology. The program will provide essential training support, mentoring, and professional experiences that will supplement his laboratory research and enhance his development as a scientist.
Chelsey earned her Ph.D. in Anatomy & Neurobiology at Boston University School of Medicine in 2020. She joined the lab of Dr. Rosalind Segal in 2021, where she is working to characterize molecular mechanisms underlying axonal degeneration in Chemotherapy Induced Peripheral Neuropathy (CIPN). The Segal Lab has recently described two pathways resulting in calpain-mediated axonopathy in rodent models of CIPN; one due to reduction of axonal bclw protein and the other through the activation of the NAD-ase, SARM1. The goal of Chelsey’s project is to validate the relevance of these pathways in the pathogenesis of human CIPN using a novel human induced sensory neuron model. To assess the effects of chemotherapy treatment on axonal degeneration, she will quantify changes in axonal morphology, calcium flux, bclw and SARM1 protein localization and concentration, calpain activity, and SARM1 metabolite production. She will then test the efficacy of bclw protein mimetic and SARM1 inhibitor treatments previously shown to have a rescue effect in rodent models of CIPN. Chelsey joined the CCBM T32 program to gain the guidance and mentorship needed to complete these metabolomic and chemoproteomic studies, and to attain academic training in the field of cancer chemical biology, which she has not had, due to primary experience in neurobiology. The training she receives in the CCBM T32 program will assist in her goal to identify therapeutic targets in nervous system and immune disorders as an independent researcher.
Mona earned her PhD from the University of Vermont in 2019. She joined the lab of Dr. Sara Buhrlage in 2021 where she works on the development of highly potent and selective ubiquitin specific protease 28 (USP28) inhibitors by a combined synthetic and computational approach. Mona was supported by the T32 training grant from Aug 2021 to Aug 2023.
Aubrey earned her Ph.D. in Respiratory Medicine from the University of Calgary in 2021. She joined the lab of Dr. Bruce Spiegelman where her research focused on expanding the repertoire of phosphocreatine functions beyond its established ATP buffering and thermogenic roles. Aubrey joined the CCBM T32 program to obtain the scientific training and career development experiences to achieve her goal of independent investigator studying metabolism and viral infections. She has recently left the program to continue her postdoctoral training at the Salk Institute in California.
Erika earned her Ph.D. in Chemistry from University of Maryland in 2020. She joined the lab of Dr. Nika Danial where she investigated the contribution of metabolic alterations to the growth of low-grade gliomas (PLGAs) — the most common brain tumors in children. Erika’s research combines analytical chemistry and biochemical tools to comprehensively map and functionalize metabolic distinctions associated with these oncogenic drivers in order to define actionable metabolic vulnerabilities. She joined the CCBM T32 training program to gain the academic and professional training needed to attain her goal of becoming an independent scientist. After completing her T32 training, she has transitioned into a role in industry.
Conor earned his PhD from the University of Minnesota in 2020. Shortly after, he joined the lab of Pere Puigserver where he studies mechanisms of cell death and cell survival in mitochondrial diseases (MDs). Conor’s project, using biochemical, genetic, and proteomic approaches, seeks to determine the precise mechanism of action toward signaling pathways that initiate at the mitochondrial ribosome upon tetracycline treatment. Conor joined the CCBM T32 training program to gain training in science and career development toward his goal of establishing his own research lab to study metabolism, disease, and therapy. After the completion of his T32 he continues his training in Puigserver lab.
Ben earned his PhD from the University of Michigan in 2020. He joined the lab of Dr. William Kaelin where he investigated degradation of Forkhead Box A1 (FOXA1), a pioneer transcription factor specifically essential in estrogen receptor-positive (ER+) breast cancer. Ben made important steps towards employing gain of signal (or “up”) assays for genetic and chemical screens to identify genetic mediators and pharmacologic compounds that degrade FOXA1. After completing his training in the CCBM program, Ben has transitioned into the role of a Senior Scientist at Odyssey Therapeutics.
Xiaofeng earned his PhD from the University of Massachusetts Boston in 2019. He joined the lab of Dr. Jun Qi where his research focused on establishing biological rationales for hematologic malignancy therapy by using novel small molecules as chemical probes. He also investigated the consequences of selective knockdown of the histone lysine demethylase, KDM5A, a transcriptional activator of MYC target genes. Xiaofeng was on the training grant from 2019 to 2021, and is currently Senior Scientist at Cerevel Therapeutics, a biopharmaceutical company focused on developing treatments for neuroscience diseases.
Narek earned his PhD from the University of Southern California in 2019. He joined the lab of Dr. Ed Chouchani where he investigated pharmacological approaches to treating obesity using a chemoproteomic platform to identify covalent scaffolds that target metabolic proteins. Narek joined the CCBM T32 program in 2019 and received two years of funding thanks to the progress he made in his research. Narek is currently a Principal Scientists at the Novartis Institute for Biomedical Research.
Kedar earned his Ph.D. from Purdue University in 2020. He joined the lab of Dr. Eric Fischer, where he studied the structural basis of targeted protein degradation. Kedar joined the CCBM T32 program to gain the scientific and professional development training needed to set him up for success in an independent research career. Kedar was awarded an F32 postdoctoral fellowship in 2021, and transitioned into a role in industry in early 2022. He is currently a Senior Scientist at AbbVie, in Targeted Protein Degradation Platform Group.
Matt earned his PhD from Yale University in 2019. He joined the lab of Dr. Justin Kim where he aimed to develop a platform for the discovery of macrocyclic peptide therapeutics. Matt was part of the CCBM T32 training program in 2020 and received training for a year. Since starting in Entrada Therapeutics in 2020, he has been promoted several times and is currently Senior Scientist I in Discovery Chemistry.
Laura earned her PhD from Yale University in 2017. She joined the lab of Dr. Kornelia Polyak where she studies stromal-induced heterogeneity of tumors and epigenetic regulation in therapeutic resistance. Laura was part of the CCBM Training Program from 2019 to 2021. Laura is currently a Senior Scientist at AstraZeneca.
Jon earned his PhD from the University of Berkeley in 2015. He joined the lab of Dr. Hari Arthanari where he studied the structural basis of transcription factor sequence specificity and function, especially focusing on the interaction of transcriptional activation domains (TADs) with the KIX domains of transcriptional mediators such as MED15. Jon was part of CCBM Training from 2019 to 2021. Currently, Jon is a Scientist II at Rgenta Therapeutics, a company focused on developing small molecule RNA-targeting medicines for cancer and neurological disorders.
Laura earned her PhD from Tuft University in 2017. She joined the lab of Dr. William Kaelin where she investigated the molecular basis of heterogeneous dependence of clear cell renal carcinoma cells (ccRCC) on Hypoxia Inducible Factor (HIF)2 alpha in preclinical models and the clinic. Laura developed mouse models and used CRISPR screens and molecular profiling to identify factors associated with HIF2 alpha dependence. She was part of the CCBM T32 training program from 2019 to 2021. Laura is currently a Senior Scientist in Odyssey Therapeutics, a biotech company that is developing next-generation precision medicines for cancer and inflammatory diseases.